Special Issue

SARS-CoV-2 Serology for the Rapid Diagnosis of COVID-19

Message from the Guest Editor

Serological tests also vary according to the viral antigens measured. Spike proteins (S) and nucleocapsid proteins (N) are the viral antigens used to detect antibodies for SARS-CoV-2, with the intended use to identify whether an individual was recently or previously infected by the virus. These serology tests can be broadly categorized by their readout platforms used to detect SARS-CoV-2 antibodies: enzyme immunoassay, high-throughput; enzyme immunoassay, medium-throughput; lateral flow assay; and total neutralizing antibodies. A reliable serology test to rapidly quantify neutralizing antibody levels in a high-throughput manner is essential for diagnosis, vaccine development, and antiviral development—especially once a minimal threshold of nAb has been defined for disease prevention in the near future. Even in a postvaccination era, serology tests will remain critical for studying both individuals' and the community's protective immunity to safeguard public health around the world. We would like to invite you to contribute with an original report, original observation, or review to highlight the new trends in serology tests for COVID-19.

Guest Editor

Dr. Jesus Alberto Silvas
U.S. Army Reserves, Aurora, CO 80045, USA

Deadline for manuscript submissions

closed (31 December 2023)

Vaccines

an Open Access Journal by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed

mdpi.com/si/128563

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

mdpi.com/journal/vaccines

Vaccines

an Open Access Journal by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed

mdpi.com/journal/vaccines

About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp
Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).

MDPI